08:58 AM EST, 11/06/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) reported Q3 adjusted net income Thursday of $3.09 per diluted share, up from $1.84 a year earlier.

Analysts polled by FactSet expected $1.93.

Total revenue for the quarter ended Sept. 30 was $115.5 million, up from $51.8 million a year earlier.

For 2025, the company lifted its adjusted diluted EPS projection to between $7.40 and $7.65, from $6.70 to $7.00 previously. Analysts surveyed by FactSet expect $6.95. Full-year revenue is now projected at between $225 million and $235 million, up from $200 million to $225 million prior range. Analysts surveyed by FactSet expect $213.7 million.

Shares of the company were up 5% in recent premarket activity Thursday.